UNION trial shows 3-year event-free survival 91·3% vs 77·4%
In a prespecified interim analysis of 231 patients, the experimental group achieved a 3-year investigator-assessed event-free survival rate of 91·3% compared with 77·4% in the standard-of-care group (log-rank p=0·0029). Treatment-related serious adverse events occurred in 19% of experimental patients versus 13% of standard-of-care patients.
Primary source
PubMed record of a Phase III journal article, October 25, 2026
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Machine-summarized from the source above; not independently reported. How we use automation